Alpine Immune Sciences (NASDAQ:ALPN) released its earnings results on Monday. The biotechnology company reported ($0.38) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.02, Fidelity Earnings reports.
Alpine Immune Sciences opened at $7.98 on Tuesday, MarketBeat reports. Alpine Immune Sciences has a 1 year low of $6.85 and a 1 year high of $12.87. The company has a current ratio of 43.67, a quick ratio of 43.67 and a debt-to-equity ratio of 0.05.
Separately, Zacks Investment Research raised Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, January 15th.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.